Luteinizing-hormone Releasing Hormone Therapy and the Risk of Death From Alzheimer Disease
Luteinizing-hormone Releasing Hormone Therapy and the Risk of Death From Alzheimer Disease
复制标题
DOI：
10.1097/wad.0b013e31819cb8f4
复制
发表时间：
2010-01-01
影响因子：
2.1
通讯作者：
Chen, Ming-Hui
中科院分区：
文献类型：
--
作者：
D'Amico, Anthony V.;Braccioforte, Michelle H.;Chen, Ming-Hui
目的：我们评估了前列腺癌患者接受或不接受促黄体生成素释放激素（LHRH）激动剂治疗的阿尔茨海默病（AD）死亡风险：方法：1997年至2007年，6,647名男性接受近距离放射治疗前列腺癌（N = 1,700）或不（N = 4,947）LHRH激动剂治疗。进行竞争风险多变量回归以评估LHRH激动剂的使用是否与AD的死亡风险相关，调整轻度AD的存在和就诊时的年龄以及已知的前列腺癌预后因素。中位随访4.1年后，研究队列中1.2%（81/6，647）的患者死于AD，占所有观察到的死亡率的16%（81/506）。与未接受LHRH激动剂治疗的男性相比，接受LHRH激动剂治疗的男性中位时间为4.0个月，其AD死亡风险显著降低[校正风险比：0.45（95%置信区间，0.25-0.83）; P = 0.01]。前列腺癌患者使用LHRH激动剂与不使用相比，与AD死亡风险降低相关。
Purpose: We evaluated the risk of death from Alzheimer disease (AD) in men with prostate cancer undergoing treatment with or without a luteinizing-hormone releasing hormone (LHRH) agonist.Methods: Between 1997 and 2007, 6,647 men were treated with brachytherapy for prostate cancer with (N = 1,700) or without (N = 4,947) LHRH agonist therapy. Competing risks multivariable regression was performed to assess whether the use of a LHRH agonist was associated with the risk of death from AD adjusting for the presence of mild AD and age at presentation and known prostate cancer prognostic factors.Results: After a median follow-up of 4.1 years, 1.2% (81/6,647) of the study cohort died from AD accounting for 16% (81/506) of all observed mortality. There was a significant reduction in the risk of death from AD in men who were treated with a LHRH agonist for a median of 4.0 months as compared with those who were not [adjusted hazard ratio: 0.45 (95% confidence interval, 0.25-0.83); P = 0.01].Conclusions: LHRH agonist use as compared with no use in men with prostate cancer was associated with a decreased risk of death from AD.